Extended Data Fig. 8: Characterization of the role of RORγt and enteric β-defensins in digoxin response.
From: Identification of medication–microbiome interactions that affect gut infection
a,b, Effect of PBS or digoxin pretreatment on S. Tm ∆invA infection in SFB-colonized Rorc−/− mice. Pathogen burden (n = 8 mice per group) (a) and mortality (b) is shown. c, Effect of PBS (n = 3 per group) or digoxin pretreatment (ΔILC3 n = 4, RorcSTOP n = 5) on SFB levels in the faeces of SFB-colonized ΔILC3 mice and littermate RorcSTOP controls. d, Effect of PBS or digoxin pretreatment on SFB levels in the ileal content of SFB-monocolonized (ex-GF) Rag1-/- mice (n = 5 per group) and littermate WT SFB-monocolonized (ex-GF) controls (PBS n = 6, digoxin n = 4). A Kruskal–Wallis test followed by Dunn’s multiple comparison test was used for statistical analysis. e, Volcano plot of RNA-seq data from PBS-pretreated and digoxin-pretreated C57BL/6NTac mice. f, Volcano plot of chemokine genes from PBS-pretreated and PBS-pretreated C57BL/6NTac mice. Genes with chemokine activity were identified from the Molecular Signatures Database (MSigDB) (see methods for details). g, Defb39 expression in the ileum, caecum, and colon tissues of C57BL/6NTac mice treated with PBS or digoxin (standard regimen, n = 5 per group). h, Defb39 expression in the ileum tissue of mice (n = 4 per group) treated with PBS or digoxin on day 7 of the extended treatment regimen. In a,c,g,h, a two-sided Mann–Whitney test was used to calculate statistics. In b, the Gehan–Breslow–Wilcoxon test is used. ns, not significant.
